argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
03 jun 2016 - 07:00
Statutaire naam
argenx SE
Titel
argenx successfully closes €30 million private placement
Bericht
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it has successfully closed the €30 million transaction with predominantly US institutional investors it announced on June 1, 2016. The investors include Aquilo Capital, Burrage Capital, Dafna Capital, MPM Oncology Impact Fund and Perceptive Advisors and certain other existing and new institutional investors. 2,703,000 shares have been issued at € 11.10. The new shares are expected to be admitted to listing on Euronext Brussels next week.
Gerelateerde downloads
Datum laatste update: 18 december 2025